LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.
How this was made
The 30-second read
Why it matters
Traders can update FY 2026 valuation models using the raised constant-currency revenue and adjusted EPS ranges, while monitoring the cash flow guidance reset and the timing of supply-driven capacity expansion.
Market read
A same-day earnings and guidance update with explicit FY 2026 numbers, plus a new long-term supplier agreement, is a direct catalyst for repricing LIVN’s forward fundamentals.
What to watch
The agreement increases component availability over time, so near-term output benefits may lag; also GAAP operating income declined year over year, which could matter to some investors.
Background
LivaNova reported Q2 2026 results and simultaneously updated FY 2026 guidance, alongside operational updates including a long-term oxygenator component supply agreement and board/executive appointments.
Ticker impact
LivaNova raised full-year 2026 revenue growth to 8% to 9% and adjusted EPS to $4.30 to $4.40 after reporting Q2 results.
Likely positive bias for the next session as traders reprice FY 2026 earnings power and supply-chain continuity.
The article discloses specific Q2 financials, explicit FY guidance changes, and a new long-term supplier agreement tied to capacity and unmet demand.
Market effects
Medical device and cardiopulmonary supply-chain confidence may improve, especially for oxygenator-related manufacturing capacity.
Europe growth cited in Cardiopulmonary could support regional demand expectations.
Thermo Fisher component availability agreement may affect broader oxygenator supply dynamics over time.
Counterpoint
Adjusted free cash flow guidance was lowered to $140 million to $160 million, which could temper the equity reaction despite higher revenue and EPS.
Key entities
- companyLivaNova PLC
Nasdaq-listed medical technology company reporting Q2 2026 results and raising FY 2026 guidance.
- companyThermo Fisher Scientific
Entered into a long-term agreement with LivaNova to strengthen oxygenator component supply.
- regulatorAgenzia delle Entrate
Italian tax authority ruling recognized a discrete €81.8 million tax benefit.
